Summary
AMETEK, Inc. (AME) reported solid results for the third quarter and the first nine months of fiscal year 2024, demonstrating resilience and strategic execution. For the third quarter, net sales increased by 5.3% year-over-year to $1.71 billion, driven by contributions from recent acquisitions and favorable international demand, despite a slight organic sales decline. Diluted earnings per share remained stable at $1.47. The nine-month period showed a 6.4% increase in net sales to $5.18 billion, with diluted EPS rising to $4.26. The company's strong operational performance, coupled with effective integration of its 2023 acquisitions, particularly Paragon Medical and United Electronic Industries, contributed positively to financial results. Financially, AMETEK maintained a strong liquidity position, with operating cash flow increasing by 7.0% to $1.28 billion for the first nine months. The company also demonstrated a commitment to returning capital to shareholders, increasing its quarterly dividend by 12% and repurchasing $68.0 million in common stock during the period. The debt-to-capital ratio improved significantly to 19.7% from 27.5% at the end of the previous year, highlighting a strengthened balance sheet.
Financial Highlights
52 data points| Revenue | $1.71B |
| Cost of Revenue | $1.09B |
| Gross Profit | $615.81M |
| SG&A Expenses | $169.96M |
| Operating Expenses | $1.26B |
| Operating Income | $445.85M |
| Net Income | $340.24M |
| EPS (Basic) | $1.47 |
| EPS (Diluted) | $1.47 |
| Shares Outstanding (Basic) | 231.34M |
| Shares Outstanding (Diluted) | 232.22M |
Key Highlights
- 1Net sales for Q3 2024 increased 5.3% to $1.71 billion, driven by acquisitions and international growth, while nine-month sales rose 6.4% to $5.18 billion.
- 2Diluted EPS for Q3 2024 was $1.47 (flat year-over-year), and for the nine-month period, it increased to $4.26 ($4.19 in prior year).
- 3Operating income for Q3 2024 grew 1.8% to $445.9 million, and for the nine-month period, it increased 3.8% to $1.31 billion.
- 4Operating cash flow for the nine-month period increased 7.0% to $1.28 billion, and free cash flow was $1.20 billion.
- 5The company increased its quarterly cash dividend by 12% to $0.28 per share.
- 6Debt-to-capital ratio improved to 19.7% as of September 30, 2024, down from 27.5% at December 31, 2023.
- 7Acquisitions, including Paragon Medical and Amplifier Research, contributed significantly to sales growth, although they had a dilutive impact on segment operating margins in the short term.